Publications
- Radioimunotherapy ytrium-90 (90Y)-ibritumomab tiuxetanam in patients with folicular non-hodgkin lymphoma – experience of one departmen2010 | First Faculty of Medicine
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Diagnostika a léčba mnohočetného myelomu 2023. Doporučení České myelomové skupiny, Slovenské myelómové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Léčba belantamabem v pátém relapsu mnohočetného myelomu2023 | First Faculty of Medicine
- ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma - final results of a phase I/IIa study2023 | Faculty of Medicine in Hradec Králové
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas2022 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
Loading network view...